Skip to main content

Advertisement

SpringerLink
Log in

Clinical implications of the deregulated TP73 isoforms expression in cancer

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

TP73 is a member of the TP53 family whose expression has been observed altered in most human cancers and associated with the prognosis. TP73 translates into a complex number of isoforms with both oncogenic and tumour-suppressor functions and presents a complex cross-talk with other members of the family (TP53 and TP63). In this revision, we focus on the evidence that may support TP73 variants as prognostic markers in cancer. Nowadays, most publications in this topic highlight the association between overexpression of the oncogenic variants and failure to respond to chemotherapy and/or shorter survival. In addition, we comment on the putative possibilities that the detection through a liquid biopsy of TP73 variants may provide, and finally, the significance of determining the value of the combined alteration of the TP53 family members in the clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Amelio I, Inoue S, Markert EK, Levine AJ, Knight RA, Mak TW, et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1α degradation. Proc Natl Acad Sci USA. 2015;112:226–31.

    Article  PubMed  CAS  Google Scholar 

  2. Bahnassy AA, Zekri AR, Salem SE, Abou-Bakr AA, Sakr MA, Abdel-Samiaa AG, et al. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: prognostic and predictive values. Histol Histopathol. 2014;29:207–16.

    PubMed  CAS  Google Scholar 

  3. Becker K, Pancoska P, Concin N, Vanden Heuvel K, Slade N, Fischer M, et al. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol. 2006;29:889–902.

    PubMed  CAS  Google Scholar 

  4. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 2002;9:246–51.

    Article  PubMed  CAS  Google Scholar 

  5. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, et al. Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer. 2007;7:127.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Chen YK, Huse SS, Lin LM. Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. Clin Otolaryngol Allied Sci. 2003;28:451–5.

    Article  PubMed  CAS  Google Scholar 

  7. Chen Y, Wang X, Li F, Zhang L, Ma L, Liu Y. Relationship between expression of P27, Fragile Histidine Triad (FHT), phosphatase and tensin homolog deleted on chromosome ten (PTEN), P73, and prognosis in esophageal squamous cell carcinoma. Ann Diagn Pathol. 2015;19:33–6.

    Article  PubMed  CAS  Google Scholar 

  8. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol. 2002;33:158–64.

    Article  PubMed  CAS  Google Scholar 

  9. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 2004;64:2449–60.

    Article  PubMed  CAS  Google Scholar 

  10. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53–p73 cross-talk in vivo. Clin Cancer Res. 2005;11:8372–83.

    Article  PubMed  CAS  Google Scholar 

  11. De la Fuente M, Jones M-C, Santander-Ortega MJ, Mirenska A, Marimuthu P, Uchegbu I, et al. A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer. Nanomedicine. 2015;11:369–77.

    Article  PubMed  CAS  Google Scholar 

  12. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 2006;24:805–15.

    Article  PubMed  CAS  Google Scholar 

  13. Dulloo I, Hooi PB, Sabapathy K. Hypoxia-induced DNp73 stabilization regulates Vegf-A expression and tumor angiogenesis similar to TAp73. Cell Cycle. 2015;14:3533–9.

  14. Faridoni-Laurens L, Bosq J, Janot F, Vayssade M, Le Bihan ML, Kaghad M, et al. P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene. 2001;20:5302–12.

    Article  PubMed  CAS  Google Scholar 

  15. Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F, et al. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle. 2008;7:1587–96.

    Article  PubMed  CAS  Google Scholar 

  16. Fatt MP, Cancino GI, Miller FD, Kaplan DR. p63 and p73 coordinate p53 function to determine the balance between survival, cell death, and senescence in adult neural precursor cells. Cell Death Differ. 2014;21:1546–59.

  17. Fernandez-Alonso R, Martin-Lopez M, Gonzalez-Cano L, Garcia S, Castrillo F, Diez-Prieto I, et al. p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling. Cell Death Differ. 2015;22:1287–99.

  18. Ferru A, Denis S, Guilhot J, Gibelin H, Tourani JM, Kraimps JL, et al. Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours. Eur J Surg Oncol. 2006;32:228–30.

    Article  PubMed  CAS  Google Scholar 

  19. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, et al. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene. 2001;20:514–22.

    Article  PubMed  CAS  Google Scholar 

  20. Ganzetti G, Rubini C, Campanati A, Zizzi A, Molinelli E, Rosa L, et al. IL-17, IL-23, and p73 expression in cutaneous melanoma: a pilot study. Melanoma Res. 2015;25:232–8.

    Article  PubMed  CAS  Google Scholar 

  21. Gonzalez-Cano L, Fuertes-Alvarez S, Robledinos-Anton N, Bizy A, Villena-Cortes A, Fariñas I, et al. p73 is required for ependymal cell maturation and neurogenic SVZ cytoarchitecture. Dev Neurobiol. 2016;76:730–47.

  22. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213–23.

    Article  PubMed  CAS  Google Scholar 

  23. Guan M, Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol. 2005;58:1175–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Hamdy MS, El-Saadany ZA, Makhlouf MM, Salama AI, Ibrahim NS, Gad AA. TAp73 and ΔNp73 relative expression in Egyptian patients with lymphoid neoplasms. Tumori. 2016;. https://doi.org/10.5301/tj.5000506.

    Article  PubMed  Google Scholar 

  25. Hong SM, Cho H, Moskaluk CA, Yu E, Zaika AI. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. J Mol Histol. 2007;38:167–75.

    Article  PubMed  CAS  Google Scholar 

  26. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter Phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33:1902–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62:636–41.

    PubMed  CAS  Google Scholar 

  28. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Sakon M, Matsuura N. Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness. Int J Mol Med. 2001;8:67–71.

    PubMed  CAS  Google Scholar 

  29. Ito Y, Uramoto H, Funa K, Yoshida H, Jikuzono T, Asahi S, et al. Delta Np73 expression in thyroid neoplasms originating from follicular cells. Pathology. 2006;38:205–9.

    Article  PubMed  CAS  Google Scholar 

  30. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  31. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389:191–4.

    Article  PubMed  CAS  Google Scholar 

  32. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809–19.

  33. Kilic E, Brüggenwirth HT, Meier M, Naus NC, Beverloo HB, Meijerink JP, et al. Increased expression of p73Deltaex2 transcript in uveal melanoma with loss of chromosome 1p. Melanoma Res. 2008;18:208–13.

    Article  PubMed  CAS  Google Scholar 

  34. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, et al. p73: a multifunctional protein in neurobiology. Mol Neurobiol. 2011;43:139–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Landré V, Antonov A, Knight R, Melino G. p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression. Oncotarget. 2016;7:11785–802.

  36. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007;117:1370–80.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Leupin N, Lüthi A, Novak U, Grob TJ, Hügli B, Graber H, et al. P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2004;45:1205–7.

    Article  PubMed  CAS  Google Scholar 

  38. Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet. 2009;5:e1000680.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Liu SS, Chan KYK, Cheung ANY, Liao XY, Leung TW, Ngan HYS. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res. 2006;12:3922–7.

    Article  PubMed  CAS  Google Scholar 

  40. Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M, et al. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol. 2011;6:473–81.

    Article  PubMed  Google Scholar 

  41. Lucena-Araujo AR, Kim HT, Thomé C, Jacomo RH, Melo RA, Bittencourt R, et al. High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood. 2015;126:2302–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Meier M, den Boer ML, Meijerink JPP, Broekhuis MJC, Passier MMCJ, van Wering ER, et al. Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia. 2006;20:1377–84.

    Article  PubMed  CAS  Google Scholar 

  43. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2:605–15.

    Article  PubMed  CAS  Google Scholar 

  44. Niklison-Chirou MV, Steinert JR, Agostini M, Knight RA, Dinsdale D, Cattaneo A, et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci USA. 2013;110:18952–7.

  45. O’Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, et al. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer. 2001;85:1551–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009;16:1–12.

    Article  PubMed  CAS  Google Scholar 

  47. Park HR, Kim YW, Park JH, Maeng YH, Nojima T, Hashimoto H, Park YK. Low expression of p63 and p73 in osteosarcoma. Tumori. 2004;90:239–43.

    Article  PubMed  CAS  Google Scholar 

  48. Pozniak CD, Radinovic S, Yang A,  McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–6.

  49. Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, et al. p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res. 2003;9:5642–51.

    PubMed  CAS  Google Scholar 

  50. Rizzo MG, Giombini E, Diverio D, Vignetti M, Sacchi A, Testa U, et al. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia. 2004;18:1804–9.

    Article  PubMed  CAS  Google Scholar 

  51. Romani M, Scaruffi P, Casciano I, Mazzocco K, Lo Cunsolo C, Cavazzana A, et al. Stage-independent expression and genetic analysis of tp73 in neuroblastoma. Int J Cancer. 1999;84:365–9.

    Article  PubMed  CAS  Google Scholar 

  52. Scian MJ, Carchman EH, Mohanraj L, Stagliano KER, Anderson MAE, Deb D, et al. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene. 2008;27:2583–93.

    Article  PubMed  CAS  Google Scholar 

  53. Schuster A, Schilling T, De Laurenzi V, Koch AF, Seitz S, Staib F, Teufel A, et al. ΔNp73β is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle. 2010;9:2629–39.

    Article  PubMed  CAS  Google Scholar 

  54. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10:94–9.

  55. Soldevilla B, Díaz R, Silva J, Campos-Martín Y, Muñoz C, García V, et al. Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res. 2011;17:6029–39.

    Article  PubMed  CAS  Google Scholar 

  56. Soldevilla B, Rodríguez M, San Millán C, García V, Fernández-Periañez R, Gil-Calderón B, et al. Tumor-derived exosomes are enriched in ΔNp73, which promotes oncogenic potential in acceptor cells and correlates with patient survival. Hum Mol Genet. 2014;23:467–78.

    Article  PubMed  CAS  Google Scholar 

  57. Song D, Yue L, Wu G, Ma S, Yang H, Liu Q, et al. Evaluation of promoter hypomethylation and expression of p73 as a diagnostic and prognostic biomarker in Wilms’ tumour. J Clin Pathol. 2016;69:12–8.

    Article  PubMed  CAS  Google Scholar 

  58. Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Fürst K, et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell. 2013;24:512–27.

  59. Stiewe T, Theseling CC, Pützer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem. 2002;277:14177–85.

    Article  PubMed  CAS  Google Scholar 

  60. Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res. 2002;8:165–70.

    PubMed  CAS  Google Scholar 

  61. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.

    PubMed  CAS  Google Scholar 

  62. Thakur AK, Nigri J, Lac S, Leca J, Bressy C, Berthezene P, et al. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Cell Death Differ. 2016;23:1358–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008;22:2677–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Toumi AA, El Hadj OEA, Ben Mahmoud LK, Ben Hmida AEM, Chaar I, Gharbi L, et al. The prognostic value of p73 overexpression in colorectal carcinoma: a clinicopathologic, immunohistochemical, and statistical study of 204 patients. Appl Immunohistochem Mol Morphol. 2010;18:128–36.

    Article  PubMed  CAS  Google Scholar 

  65. Tuve S, Wagner SN, Schittek B, Pützer BM. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int J Cancer. 2004;108:162–6.

    Article  PubMed  CAS  Google Scholar 

  66. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res. 2004;10:6905–11.

    Article  PubMed  CAS  Google Scholar 

  67. Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W, et al. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene. 2008;27:2170–6.

    Article  PubMed  CAS  Google Scholar 

  68. Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, et al. Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors. Oncogene. 2010;29:5861–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, et al. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer. 2006;95:1062–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer. 2002;99:22–8.

    Article  PubMed  CAS  Google Scholar 

  71. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev. 2010;24:549–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, et al. Mutation and expression analysis of the p73 gene in prostate cancer. Prostate. 1999;39:94–100.

    Article  PubMed  CAS  Google Scholar 

  73. Yong M, Yang L, Suyila Q, Han W, Yuan H, Zhao C, et al. Expression and clinical implications of P53, P63, and P73 protein in malignant tumor of the parotid gland. Turk J Med Sci. 2014;44:875–82.

    Article  PubMed  Google Scholar 

  74. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002;196:765–80.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z, et al. p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol. 2007;114:641–50.

    Article  PubMed  CAS  Google Scholar 

  76. Zhao W, Zhang B, Guo X, Zhang X, Hu J, Hu X, et al. Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma. Cancer Biomark. 2014;14:197–202.

    Article  PubMed  CAS  Google Scholar 

  77. Zhu X, Pan X, Yang Z, Xing P, Zhang Y, Li F, et al. Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I–II cervical squamous cell carcinoma. Oncol Lett. 2015;9:2090–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge ISCIII, FIS, FEDER and Cátedra de Patrocinio UAM-Roche for funding our current research through the PI15/00246 Grant and the Grant from the MINECO (SAF2014-53209-R) and CIBERONC.

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Universitario La Paz, CIBERONC, Madrid, Spain

    N. Rodríguez

  2. Servicio de Anatomía Patológica and Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain

    A. Peláez

  3. UFIEC, ISCIII, Majadahonda, Madrid, Spain

    R. Barderas

  4. Departamento de Medicina, Facultad de Medicina, Instituto de Investigaciones Biomédicas “Alberto Sols”, CSIC-Universidad Autónoma de Madrid, CIBERONC, Madrid, Spain

    G. Domínguez

Authors
  1. N. Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Peláez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Barderas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Domínguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Domínguez.

Ethics declarations

Conflict of interest

We declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodríguez, N., Peláez, A., Barderas, R. et al. Clinical implications of the deregulated TP73 isoforms expression in cancer. Clin Transl Oncol 20, 827–836 (2018). https://doi.org/10.1007/s12094-017-1802-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1802-3

Keywords

Search

Navigation